Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug. NPR does not offer or accept money for coverage or interviews.

Anyone who makes such an offer or request is not an NPR employee and does not represent NPR.